Pharmaceuticals

Psoriasis Market 2026–2030: Forecasting Business Opportunities Ahead

February 18, 2026February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the psoriasis market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Psoriasis Market?

The psoriasis market size has experienced significant expansion in recent years. It is projected to increase from $28.93 billion in 2025 to $31.41 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.5%. This growth observed in prior periods can be attributed to factors such as the increasing prevalence of autoimmune skin disorders, widespread corticosteroid usage, improvements in dermatology diagnosis rates, the expansion of hospital dermatology units, and growing awareness of chronic skin diseases.

The market for psoriasis treatments is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $44.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this projected growth include an increase in approvals for biologic drugs, heightened patient understanding, a rise in severe psoriasis diagnoses, the proliferation of specialized clinics, and increased healthcare expenditure dedicated to dermatology. Key trends anticipated during the forecast period involve the greater acceptance of biologic treatments for psoriasis, the adoption of more extensive long-term disease management strategies, an escalating need for injectable psoriasis medications, the broadening of hospital and specialized dermatology services, and a concentrated effort on moderate-to-severe forms of the condition.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp

What Drivers Are Supporting Technological Adoption In The Psoriasis Market?

An increasing number of individuals afflicted with psoriasis is projected to fuel the expansion of the psoriasis market in the future. Psoriasis, a persistent autoimmune skin condition, manifests through the rapid accumulation of skin cells, resulting in inflammation, flaking, and discomfort, frequently necessitating ongoing medical care and observation. This increase in psoriasis patients stems from an overactive immune system erroneously targeting healthy skin cells, a process often initiated or worsened by environmental elements like infections, stress, or skin injuries. The expanding prevalence of psoriasis bolsters the psoriasis market by driving up the need for biologics, topical treatments, immunomodulators, and light therapy options developed to alleviate flare-ups, ameliorate symptoms, and elevate patients’ quality of life. For example, in 2025, the Global Psoriasis Atlas, a UK-based research organization dedicated to psoriasis, estimated that 43 million people had psoriasis based on diagnoses from physicians and dermatologists, whereas around 102 million people reported having the condition through self-reported cases. Consequently, the growing incidence of psoriasis patients is a key driver for the psoriasis market’s growth.

What Segment Types Are Examined In The Psoriasis Market?

The psoriasis market covered in this report is segmented –

1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor

2) By Drug Types: Small molecules, Biologics

3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce

Subsegments:

1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)

2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)

3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)

Which Trends Are Influencing The Development Of The Psoriasis Market?

Leading companies in the psoriasis market are concentrating on advancements in product innovation and formulation, such as autoinjector delivery systems for biosimilars. This focus aims to enhance patient adherence, convenience, and treatment outcomes while preserving the efficacy and safety profiles of reference biologics. These new solutions facilitate self-administration, reduce injection discomfort, and promote wider adoption of biosimilar therapies across Europe and other markets. For example, in May 2025, Sandoz, a biopharmaceutical company based in Switzerland, introduced the Pyzchiva autoinjector, which represents the first commercially available autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is engineered to offer simple, accurate, and patient-friendly administration of biosimilar ustekinumab, thereby supporting improved adherence for the management of chronic psoriasis. This launch underscores a market trajectory towards improving patient-centric delivery options for both biologics and biosimilars, thereby increasing accessibility and convenience for individuals managing psoriasis.

Who Are The Prominent Global Companies Shaping The Psoriasis Market Landscape?

Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Psoriasis Market?

North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Psoriasis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2414&type=smp

Browse Through More Reports Similar to the Global Psoriasis Market 2026, By The Business Research Company

Psoriasis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Dermatology Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795